Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Murray (2006)
Challenges of tuberculosis controlCanadian Medical Association Journal, 174
(2022)
Global tuberculosis report 2022
A Lohiya, R Suliankatchi Abdulkader, RS Rath (2020)
Prevalence and patterns of drug resistant pulmonary tuberculosis in India—a systematic review and meta-analysisJ Glob Antimicrob Resist, 22
National TB prevalence survey in India 2019-2021
S Murray (2006)
Challenges of tuberculosis control [published correction appears in CMAJ. 2006;174(6):815]CMAJ, 174
D Yee, C Valiquette, M Pelletier, I Parisien, I Rocher, D Menzies (2003)
Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosisAm J Respir Crit Care Med, 167
(2022)
National TB elimination program (India)
S. Shivekar, V. Kaliaperumal, Usharani Brammacharry, Anbazhagi Sakkaravarthy, C. Raj, C. Alagappan, M. Muthaiah (2020)
Prevalence and factors associated with multidrug-resistant tuberculosis in South IndiaScientific Reports, 10
A. Dalal, A. Pawaskar, M. Das, Ranjana Desai, P. Prabhudesai, P. Chhajed, S. Rajan, D. Reddy, Sajit Babu, T. Jayalakshmi, P. Saranchuk, C. Rodrigues, P. Isaakidis (2015)
Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Greater Metropolitan Mumbai: Trends over TimePLoS ONE, 10
A. Lohiya, Rizwan Abdulkader, Ramashankar Rath, O. Jacob, P. Chinnakali, A. Goel, S. Agrawal (2020)
National and sub-national level prevalence and patterns of drug resistant pulmonary tuberculosis - a systematic review and meta-analysis of Indian studies.Journal of global antimicrobial resistance
1171498 APHXXX10.1177/10105395231171498Asia Pacific Journal of Public HealthKochhar et al research-article2023 Short Communication Asia Pacific Journal of Public Health 1 –3 Tuberculosis in India: Challenges, © 2023 APJPH Article reuse guidelines: sagepub.com/journals-permissions Initiatives, and Recommendations https://doi.org/10.1177/10105395231171498 DOI: 10.1177/10105395231171498 journals.sagepub.com/home/aph 1 2 Gunjan Kochhar, MBBS , Omer Ahmed Shaikh, MBBS , 2 2 Rameel Muhammad Aftab, MBBS , Manisha Essarani, MBBS , 3 4 Sidhant Ochani, MBBS , and Kaleem Ullah, FCPS Mycobacterium tuberculosis is a respiratory pathogen that turn, noncompliance increases the risk of drug resistance to primarily affects the lungs. The incidence (new cases per first-line agents such as isoniazid and rifampicin. Unregulated year per million population) of tuberculosis (TB) in India for private prescription of these drugs has led to a rise in resis- 2021 is 210 cases per 1 00 000 population. India accounts for tant forms. More extensive testing for rifampicin resistance 28% of the total new cases worldwide. The highest number is required in today’s world to prevent suboptimal treatment of cases are reported from the Delhi region, that is, 747 cases and further evolution of resistant cases. Adverse drug reac- per 1 00 000 population, followed by Haryana (477) and tions of first-line agents
Asia Pacific Journal of Public Health – SAGE
Published: May 1, 2023
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.